SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Circulating tumor DNA as a predictive biomarker for colorectal cancer postsurgical recurrence: a systematic review and meta-analysis.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Circulating tumor DNA in neoadjuvant therapy for solid tumors.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeColorectal carcinoma constitutes a predominant etiology of oncological mortality globally. This systematic review and meta-analysis elucidated the prognostic utility of circulating tumor DNA (ctDNA) as a predictive biomarker for postsurgical recurrence in colorectal cancer patients.
methodsTwo independent investigators conducted systematic literature search across PubMed, Web of Science, Embase, Scopus, and clinical trial registries. Studies investigating ctDNA prognostic significance for colorectal cancer recurrence were incorporated. Random-effects models were implemented utilizing restricted maximum likelihood methodology. The study quality was assessed using Newcastle-Ottawa Scale.
resultsFollowing screening of 2259 records, 11 studies were incorporated. ctDNA-positive patients exhibited significantly elevated recurrence risk as compared to ctDNA-negative counterparts (pooled HR: 2.34; 95% CI: 1.90-2.79; p < 0.001). Moderate heterogeneity was observed (I
conclusionsctDNA represents a robust prognostic biomarker for postsurgical colorectal cancer recurrence with consistent cross-platform performance. Enhanced prognostic value in adjuvant chemotherapy patients supports personalized surveillance implementation, though methodological standardization remains warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.